<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02191384</url>
  </required_header>
  <id_info>
    <org_study_id>ASLST-MDD-Ⅱa-1401</org_study_id>
    <secondary_id>2012ZX09303-003</secondary_id>
    <nct_id>NCT02191384</nct_id>
  </id_info>
  <brief_title>Comparison of Orcinoside With Placebo in Treatment of MDD</brief_title>
  <official_title>Proof Of Concept Study of Orcinoside in the Treatment of Major Depressive Disorder(MDD): a Randomized, Double-Blind, Placebo-Paralleled,Dose-Finding, Multicenter Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Mental Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kun Ming KingBio Biotechnology Co. LTD</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Mental Health Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Orcinoside Capsule in different doses are
      effective in the treatment of Depression.

      And to explore the preliminary information of safety and efficacy of Orcinoside Capsule in
      the Chinese Patients with Depression.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2014</start_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change of total score from baseline in MADRS and HAMD scale</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>response rate and remission rate</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>decreasing rate from baseline in MADRS</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>decreasing rate from baseline in HAMD scale</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in HAMA</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGI(CGI-S,CGI-I)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sleep VAS scale.</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>vital sign</measure>
    <time_frame>6 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>AE(adverse events)</measure>
    <time_frame>6 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>laboratory examination</measure>
    <time_frame>6 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>ECG</measure>
    <time_frame>6 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>C-SSRS</measure>
    <time_frame>6 weeks</time_frame>
  </other_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Major Depressive Disorder (MDD)</condition>
  <arm_group>
    <arm_group_label>Orcinoside 25mg per day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Orcinoside 50mg per day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Orcinoside 100mg per day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Orcinoside 200mg per day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Orcinoside 400mg per day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Orcinoside 600mg per day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Orcinoside</intervention_name>
    <description>oral, twice per day</description>
    <arm_group_label>Orcinoside 25mg per day</arm_group_label>
    <arm_group_label>Orcinoside 50mg per day</arm_group_label>
    <arm_group_label>Orcinoside 100mg per day</arm_group_label>
    <arm_group_label>Orcinoside 200mg per day</arm_group_label>
    <arm_group_label>Orcinoside 400mg per day</arm_group_label>
    <arm_group_label>Orcinoside 600mg per day</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult with primary diagnosis of major depressive disorder based on the criteria of
             DSM-IV-TR, single episode or recurrent episode, not accompanied with psychotic
             symptoms. Coding of diagnosis included:

        296.21 MDD single episode, mild 296.22 MDD single episode, moderate 296.31 MDD recurrent
        episode, mild 296.32 MDD recurrent episode, moderate

          -  The subject is an outpatient.

          -  The subject is a man or woman,aged≥18 and ≤65 years.

          -  The total score of HAMD-17 is ≥18 and ≤24 in both screening visit and baseline visit.

          -  The subject is willing to take birth control measures during study period and one
             month after study.

          -  The subject understands and consents to takes part in this clinical trials. The
             subjects should sign informed consent.

        Exclusion Criteria:

          -  The subject has a significant risk of suicide according to the investigator's opinion
             or has a score ≥3 on item 3(suicide assessment) of the HAMD or has made a suicide
             attempt.

          -  The subject has a current DSM-Ⅳ-TR axisⅠpsychiatric diagnosis other than depression.

          -  When the HAMD17 score of baseline visit compares with the screening visit, the
             decreasing rate is ≥25%.

          -  The subject has a current diagnosis or history of depression due to any other
             psychotic disorder or a general medical condition, bipolar disorder, or depression
             accompanied with psychotic symptoms.

          -  Any unstable cardiovascular, hepatic, renal, endocrine(thyroid gland dysfunction),
             blood,or other medical disease. Had a history of seizure disorder or other brain
             organic disorders.

          -  The subject has a diagnosis of alcohol or other substance abuse or dependence at least
             1 years prior to the baseline visit.

          -  Known hypersensitivity to Common Curculigo Rhizome or other drugs.

          -  Women who were pregnant, breast-feeding, or planning to become pregnant during study.
             Men who have request to fertility within half of year.

          -  Clinically significant electrocardiographic(ECG) abnormalities or abnormal laboratory
             values(eg. Hepatic function above 1.5 times of clinical toplimit, renal function above
             toplimit, blood glucose above toplimit, cardiac troponin abnormal, thyroid gland
             examine index significantly abnormal).

          -  The subject uses antidepressant drug normally before 2 weeks of screening, and stops
             using psychotropic drug less than 7 half-life period (monoamine oxidase inhibitor more
             than 2 weeks, fluoxetine more than 1 month).

          -  The subject has accepted electroconvulsive therapy within 3months.

          -  The subject has accepted system psychotherapy within 3 months.

          -  The compliance of the subject is poor.

          -  The subject has participated in a drug clinical trial within 30 days before screening.

          -  The investigator think the subject is unsuitable to enrol in this clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huafang LI, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Mental Health Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Huafang LI, MD PhD</last_name>
    <phone>86-21-34773128</phone>
    <email>lhlh_5@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University Sixth Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongyan ZHANG, MD</last_name>
      <phone>86-13601237138</phone>
    </contact>
    <investigator>
      <last_name>Hongyan ZHANG, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guangzhou Brain Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510370</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhenhuan ZHAO, MD</last_name>
      <phone>86-13902296157</phone>
    </contact>
    <investigator>
      <last_name>Zhenhuan ZHAO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hebei Province Mental Health Center</name>
      <address>
        <city>Baoding</city>
        <state>Hebei</state>
        <zip>071000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keqing LI, MD</last_name>
      <phone>86-13703288007</phone>
    </contact>
    <investigator>
      <last_name>Keqing LI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wuhan Mental Health Center</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maosheng FANG, MD PhD</last_name>
      <phone>86-13554013182</phone>
    </contact>
    <investigator>
      <last_name>Maosheng FANG, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nanjing Brain Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ning ZHANG, MD</last_name>
      <phone>86-13851588810</phone>
    </contact>
    <investigator>
      <last_name>Ning ZHANG, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wuxi Mental Health Center</name>
      <address>
        <city>Wuxi</city>
        <state>Jiangsu</state>
        <zip>214151</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guoqiang WANG, MD</last_name>
      <phone>86-13358118908</phone>
    </contact>
    <investigator>
      <last_name>Guoqiang WANG, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai Mental Health Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huafang LI, MD PhD</last_name>
      <phone>86-21-34773128</phone>
      <email>lhlh_5@163.com</email>
    </contact>
    <investigator>
      <last_name>Huafang LI, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>the first affiliated hospital of Xi'an Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chengge GAO, MD</last_name>
      <phone>86-13572903682</phone>
    </contact>
    <investigator>
      <last_name>Chengge GAO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Xi'an Mental Health Center</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jianguo SHI, MD</last_name>
      <phone>86-13991987261</phone>
    </contact>
    <investigator>
      <last_name>Jianguo SHI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Kunming Medical University</name>
      <address>
        <city>Kunming</city>
        <state>Yunnan</state>
        <zip>650032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiufeng XU, MD</last_name>
      <phone>86-13888261558</phone>
    </contact>
    <investigator>
      <last_name>Xiufeng XU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Wang ZH, Huang J, Ma XC, Li GY, Ma YP, Li N, Wang JH. Phenolic glycosides from Curculigo orchioides Gaertn. Fitoterapia. 2013 Apr;86:64-9. doi: 10.1016/j.fitote.2013.01.008. Epub 2013 Jan 23.</citation>
    <PMID>23353659</PMID>
  </reference>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 9, 2014</study_first_submitted>
  <study_first_submitted_qc>July 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2014</study_first_posted>
  <last_update_submitted>March 5, 2015</last_update_submitted>
  <last_update_submitted_qc>March 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Mental Health Center</investigator_affiliation>
    <investigator_full_name>LI, Huafang</investigator_full_name>
    <investigator_title>Executive Director of MICT</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

